71st Heidelberg Grand Round - Sarcoma

Europe/Berlin
Description

 

 

 

 

 

This year, the NCT Heidelberg is again organizing several Heidelberg Grand Rounds. The format is aimed at clinicians as well as  researchers and provides a platform for effective scientific exchange. Recognized experts will present the latest clinical and research results in selected oncological fields.

We look forward to welcoming you to the virtual conference room.  

Please note that the time indicated corresponds to Central European Time (CET).

Presented by: 

Prof. Dr. Stefan Fröhling 
National Center for Tumor Diseases (NCT) Heidelberg 

Dr. Priya Chudasama
German Cancer Research Center (DKFZ) 

 

Participation is free of charge. Registration online is possible until 08 November. 


Thanks to our sponsor: 

PharmaMar GmbH - 1.000 €
 

The NCT Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and German Cancer Aid (DKH).

Organizer: Heidelberg University Hospital (UKHD)
Event language: English

Note:  If the registration form does not open, please change your browser (e.g. to Google Chrome, Firefox or Microsoft Edge) and try again.

    • 16:00 16:30
      Genetic and epigenetic mechanisms driving pediatric sarcomas 30m

      Ana Banito studied biology at the University of Lisbon before proceeding with her PhD studies at the Imperial College of London. After being awarded an EMBO long term fellowship she moved to New York where she performed her postdoctoral studies at the Memorial Sloan Kettering Cancer Center. There she developed an interest in the field of sarcoma and more specifically worked on the molecular mechanisms underlying the oncogenic activity of the gene fusion driving synovial sarcoma. For the last three years she is leading the soft-tissue sarcoma laboratory at the German cancer research center working towards understanding epigenetic mechanisms in pediatric sarcomas and developing new models to study these diseases.

      Speaker: Dr Ana Banito (German Cancer Research Center (DKFZ))
    • 16:30 17:00
      Utility of comprehensive molecular profiling in the sarcoma clinic 30m

      Dr. Mrinal Gounder, MD, is an internationally recognized, medical oncologist and holds dual appointment in sarcoma and early drug development (phase 1) programs at MSKCC. He specializes in developing new drugs in cancer with a specific focus on sarcoma, a rare and devastating cancer that affects children, adolescents, and adults. He joined MSKCC in 2008 and specializes in personalized medicine, where genetic testing of cancer is used to inform the right therapies for an individual patient. He is the principal investigator of several global clinical trials (phase I – III) evaluating promising new drugs for sarcoma and many other solid cancers. He was the global lead for the study that led to FDA approval of tazemetostat in sarcoma. His original research has been published in the New England Journal of Medicine, Journal of Clinical Oncology, Lancet Oncology, Nature Medicine, and others. His research contributions to drug development in rare cancers were recognized as the top 10 Advances of the Year in 2018 in the field of oncology. He is also the MSKCC Physician Ambassador to India and Asia, and is passionate about building collaborations to improve access to patient care and collaborate on education, graduate medical training, and advancing cancer research and clinical trials globally.

      Speaker: Dr Mrinal Gounder (Memorial Sloan Kettering Cancer Center (MSKCC))
    • 17:00 17:30
      Metabolic reprogramming and liquid biopsy studies in benign and malignant soft tissue tumors 30m

      Joanna Przybyl received a joint Ph.D. degree in biomedical sciences from KU Leuven, Belgium and Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland. Her doctoral studies focused on identifying new prognostic and predictive markers for soft tissue sarcoma. She then joined the laboratory of Dr. Matt van de Rijn in the Department of Pathology at Stanford University, where she completed her postdoctoral training in computational biology. During her postdoctoral studies, Dr. Przybyl demonstrated potential clinical utility of ctDNA monitoring in patients with leiomyosarcoma and leiomyoma, discovered activation and prognostic role of hexosamine biosynthesis pathway in leiomyosarcoma, and identified macrophage infiltration in undifferentiated uterine sarcomas. In 2021, Dr. Przybyl joined the Department of Surgery of the McGill University and the Cancer Research Program of the Research Institute of the McGill University Health Centre (RI-MUHC) to pursue research program focused on the clinical applications of liquid biopsies and metabolic reprogramming in sarcoma. Dr. Przybyl is also an Associate Member in the Department of Pathology of the McGill University.

      Speaker: Dr Joanna Przybyl (McGill University )
    • 17:30 18:00
      Improving lives and accelerating cures for chordoma patients 30m

      Josh Sommer is a survivor of a rare cancer called chordoma, and the
      co-founder and Executive Director of the Chordoma Foundation, a nonprofit working to improve the lives of those affected by chordoma, and lead the search for a cure.
      Under Josh’s leadership, since 2007, the Foundation has built a global movement of patients, doctors, scientists and drug companies working together to bring about better treatments, better care and better experiences for all affected by chordoma. By creating a vibrant research ecosystem and proactively investing in high-impact research, the Foundation has dramatically increased the speed and efficiency of the treatment-development process, resulting in a pipeline of seven clinical trials in the span of 10 years.
      For this work, Josh has been named by ABC News as a Person of the Year and twice was one of Forbes’ 30 under 30 transforming science and healthcare.

      Speaker: Josh Sommer (Chordoma Foundation)